Bright Minds Biosciences (DRUG) Assets Average (2021 - 2026)
For the quarter ending Q1 2026, Assets Average changed N/A year-over-year to $144.6 million, compared with a TTM value of $144.6 million through Mar 2026, changed N/A, and an annual FY2025 reading of $32.9 million, changed N/A over the prior year.
Bright Minds Biosciences (DRUG) has disclosed Assets Average for 1 consecutive years, with $144.6 million as the latest value for Q1 2026.
- Assets Average reached $144.6 million in Q1 2026 per DRUG's latest filing.
- Across five years, Assets Average topped out at $144.6 million in Q1 2026 and bottomed at $144.6 million in Q1 2026.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 13.04 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | 33.42 Mn |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 1.72 Bn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | 331.70 Mn |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | 40.89 Mn |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 26.06 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 40.71 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | 26.03 Mn |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 5.05 Bn |
| 10 | Bright Minds Biosciences | 464.72 Mn | 405.19 Mn | - | 144.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 144.56 Mn |
| Dec 31, 2025 | 63.26 Mn |
| Sep 30, 2025 | 49.62 Mn |
| Jun 30, 2025 | 38.62 Mn |
| Mar 31, 2025 | 40.58 Mn |
| Dec 31, 2024 | 23.14 Mn |
| Sep 30, 2024 | 4.53 Mn |
| Jun 30, 2024 | 4.72 Mn |
| Mar 31, 2024 | 4.95 Mn |
| Dec 31, 2023 | 5.10 Mn |
| Sep 30, 2023 | 5.71 Mn |
| Jun 30, 2023 | 6.84 Mn |
| Mar 31, 2023 | 7.95 Mn |
| Dec 31, 2022 | 8.89 Mn |
| Sep 30, 2022 | 8.09 Mn |
| Jun 30, 2022 | 8.10 Mn |
| Mar 31, 2022 | 10.76 Mn |
| Dec 31, 2021 | 14.07 Mn |